ArticleJournal of Korean medical science2023
Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011-2017: A Retrospective Cohort Study (Korean TB-POST).
Article in Journal of Korean medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Treatment outcomes and associated factors among patients with drug-resistant tuberculosis in Ethiopia: A retrospective cohort study.IJID regions · 2026Article
- Drug Resistance in Extrapulmonary Tuberculosis in Korea, 2010-2019: A Comparison With Pulmonary Tuberculosis.Journal of Korean medical science · 2026Article
- Overview of Tuberculosis Cases Reported in 2024 in the Capital Region: Seoul Metropolitan City, Incheon Metropolitan City, Gyeonggi-do, and Gangwon State.Jugan geon-gang gwa jilbyeong · 2026Article
- Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success.IJTLD open · 2026Article
- Magnitude of poor multidrug-resistant tuberculosis treatment outcome among multidrug-resistant tuberculous patients at tertiary hospital, South West Ethiopia.Annals of clinical microbiology and antimicrobials · 2025Article
- Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China.Scientific reports · 2025Article
- The impact of population ageing on tuberculosis incidence, mortality, and case fatality in South Korea: a nationwide retrospective study.ERJ open research · 2025Article
- Tuberculosis Notification and Incidence: Republic of Korea, 2023.Tuberculosis and respiratory diseases · 2025Article
- Examining the efficacy of treatment outcomes for patients with pulmonary tuberculosis in Western China: A retrospective study in a region of high incidence.BMC public health · 2025Article
- Comparison of Patients Who Were Not Evaluated and Lost to Follow-Up with Multidrug/Rifampin-Resistant Tuberculosis in South Korea.Yonsei medical journal · 2025Article
- Prevalence and epidemic pattern of ecdemic multidrug-resistant tuberculosis during 2012-2022 in Hangzhou, China: implication for public health strategies.BMC public health · 2024Article
- Epidemiological characteristics, diagnosis and treatment effect of rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Guizhou Province.BMC infectious diseases · 2024Article
- Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea.The Korean journal of internal medicine · 2024Article
- Clinical course of respiratory tuberculosis relapses in the Kazakh population depending on HLA-DRB1 gene alleles.Virusdisease · 2024Article
- Epidemiology of first- and second-line drugs-resistant pulmonary tuberculosis in Iran: Systematic review and meta-analysis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.ERJ open research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe treatment outcomes of patients with multidrug/rifampin-resistant (MDR/RR) tuberculosis (TB) are important indicators that reflect the current status of TB management and identify the key challenges encountered by TB control programs in a country.
methodsWe retrospectively evaluated the treatment outcomes as well as predictors of unfavorable outcomes in patients with MDR/RR-TB notified from 2011 to 2017, using an integrated TB database.
resultsA total of 7,226 patients with MDR/RR-TB were included. The treatment success rate had significantly increased from 63.9% in 2011 to 75.1% in 2017 (
conclusionThe treatment outcomes of patients with MDR/RR-TB has gradually improved but increasing deaths during treatment is an emerging challenge for MDR-TB control in Korea. Targeted and comprehensive care is needed for vulnerable patients such as the elderly, patients with comorbidities, and those with low household incomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.